REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS IPRNewsWire • 12/08/22
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 11/03/22
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal DeliveryPRNewsWire • 11/03/22
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic RetinopathyPRNewsWire • 10/27/22
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMDPRNewsWire • 10/03/22
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines ConferencePRNewsWire • 09/27/22
REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual MeetingPRNewsWire • 09/26/22
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual SymposiumPRNewsWire • 08/31/22
Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage DevelopmentSeeking Alpha • 08/29/22
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual SymposiumPRNewsWire • 08/23/22
REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual ConferencePRNewsWire • 08/10/22
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/05/22
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 08/03/22
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS IIPRNewsWire • 08/03/22
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to DeclineZacks Investment Research • 08/01/22
REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational HighlightsPRNewsWire • 08/01/22